Inflammation and the pathogenesis of diabetic nephropathy

Clinical Science

Volumn 124, Issue 3, 2013, Pages 139-152

  Wada, Jun ^a   Makino, Hirofumi ^a  

^a OKAYAMA UNIVERSITY   (Japan)

Author keywords

Adhesion molecule; Adipokine; Chemokine; Cytokine; Diabetic nephropathy; Nuclear receptor; Transcription factor

Indexed keywords

ADIPONECTIN; ADVANCED GLYCATION END PRODUCT; CHEMOKINE RECEPTOR CCR2; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1; INTERLEUKIN 18; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 6; LEPTIN; MONOCYTE CHEMOTACTIC PROTEIN 1; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; POLYOL; PROTEIN KINASE C; STEROL REGULATORY ELEMENT BINDING PROTEIN; TRANSCRIPTION FACTOR NFAT; TRANSCRIPTION FACTOR SP1; TUMOR NECROSIS FACTOR ALPHA; VASCULAR CELL ADHESION MOLECULE 1; AUTACOID; CYTOKINE;

ALLELE; ARTICLE; BODY MASS; CELL EXPANSION; CELL METABOLISM; CHEMOTAXIS; CHRONIC KIDNEY DISEASE; COPY NUMBER VARIATION; DIABETIC NEPHROPATHY; DISEASE COURSE; EXTRACELLULAR MATRIX; GLOMERULOSCLEROSIS; HUMAN; HYPERGLYCEMIA; INFLAMMATION; INNATE IMMUNITY; KIDNEY FAILURE; MACROPHAGE; MOLECULARLY TARGETED THERAPY; NONHUMAN; OBESITY; PATHOGENESIS; PODOCYTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; BIOLOGICAL MODEL; CHRONIC KIDNEY FAILURE; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; REVIEW; SIGNAL TRANSDUCTION;

CYTOKINES; DIABETIC NEPHROPATHIES; DISEASE PROGRESSION; HUMANS; INFLAMMATION; INFLAMMATION MEDIATORS; KIDNEY FAILURE, CHRONIC; MODELS, BIOLOGICAL; SIGNAL TRANSDUCTION;

EID: 84872041647     PISSN: 01435221     EISSN: None     Source Type: Journal    
DOI: 10.1042/CS20120198     Document Type: Article

References (156)

1. Gaede, P., Lund-Andersen, H., Parving, H. H. and Pedersen, O. (2008) Effect of a multifactorial intervention on mortality in type 2 diabetes. N. Engl. J. Med. 358, 580-591
2. Gaede, P., Vedel, P., Larsen, N., Jensen, G. V., Parving, H. H. and Pedersen, O. (2003) Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N. Engl. J. Med. 348, 383-393
3. Gaede, P., Vedel, P., Parving, H. H. and Pedersen, O. (1999) Intensified multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: the Steno type 2 randomised study. Lancet 353, 617-622
4. Rivero, A., Mora, C., Muros, M., Garcia, J., Herrera, H. and Navarro-Gonzalez, J. F. (2009) Pathogenic perspectives for the role of inflammation in diabetic nephropathy. Clin. Sci. 116, 479-492
5. Navarro-Gonzalez, J. F., Mora-Fernandez, C., Muros de Fuentes, M. and Garcia-Perez, J. (2011) Inflammatory molecules and pathways in the pathogenesis of diabetic nephropathy. Nat. Rev. Nephrol. 7, 327-340
6. Makino, H., Yamasaki, Y., Haramoto, T., Shikata, K., Hironaka, K., Ota, Z. and Kanwar, Y. S. (1993) Ultrastructural changes of extracellular matrices in diabetic nephropathy revealed by high resolution scanning and immunoelectron microscopy. Lab. Invest. 68, 45-55
7. Donath, M. Y. and Shoelson, S. E. (2011) Type 2 diabetes as an inflammatory disease. Nat. Rev. Immunol. 11, 98-107
8. Makino, H., Kashihara, N., Sugiyama, H., Kanao, K., Sekikawa, T., Okamoto, K., Maeshima, Y., Ota, Z. and Nagai, R. (1996) Phenotypic modulation of the mesangium reflected by contractile proteins in diabetes. Diabetes 45, 488-495
9. Anders, H. J. and Ryu, M. (2011) Renal microenvironments and macrophage phenotypes determine progression or resolution of renal inflammation and fibrosis. Kidney Int. 80, 915-925
10. Sugimoto, H., Shikata, K., Hirata, K., Akiyama, K., Matsuda, M., Kushiro, M., Shikata, Y., Miyatake, N., Miyasaka, M. and Makino, H. (1997) Increased expression of intercellular adhesion molecule-1 (ICAM-1) in diabetic rat glomeruli: glomerular hyperfiltration is a potential mechanism of ICAM-1 upregulation. Diabetes 46, 2075-2081
11. Koya, D., Haneda, M., Nakagawa, H., Isshiki, K., Sato, H., Maeda, S., Sugimoto, T., Yasuda, H., Kashiwagi, A., Ways, D. K. et al. (2000) Amelioration of accelerated diabetic mesangial expansion by treatment with a PKCβ inhibitor in diabetic db/db mice, a rodent model for type 2 diabetes. FASEB J. 14, 439-447
12. Ramasamy, R., Yan, S. F. and Schmidt, A. M. (2011) Receptor for AGE (RAGE): signaling mechanisms in the pathogenesis of diabetes and its complications. Ann. N.Y. Acad. Sci. 1243, 88-102
13. Sourris, K. C. and Forbes, J. M. (2009) Interactions between advanced glycation end-products (AGE) and their receptors in the development and progression of diabetic nephropathy: are these receptors valid therapeutic targets. Curr. Drug Targets 10, 42-50
14. Chung, A. C., Zhang, H., Kong, Y. Z., Tan, J. J., Huang, X. R., Kopp, J. B. and Lan, H. Y. (2010) Advanced glycation end-products induce tubular CTGF via TGF-β-independent Smad3 signaling. J. Am. Soc. Nephrol. 21, 249-260
15. Alderson, N. L., Chachich, M. E., Youssef, N. N., Beattie, R. J., Nachtigal, M., Thorpe, S. R. and Baynes, J. W. (2003) The AGE inhibitor pyridoxamine inhibits lipemia and development of renal and vascular disease in Zucker obese rats. Kidney Int. 63, 2123-2133
16. Figarola, J. L., Loera, S., Weng, Y., Shanmugam, N., Natarajan, R. and Rahbar, S. (2008) LR-90 prevents dyslipidaemia and diabetic nephropathy in the Zucker diabetic fatty rat. Diabetologia 51, 882-891
17. Kim, Y. S., Kim, J., Kim, C. S., Sohn, E. J., Lee, Y. M., Jeong, I. H., Kim, H., Jang, D. S. and Kim, J. S. (2011) KIOM-79, an inhibitor of AGEs-protein cross-linking, prevents progression of nephropathy in Zucker diabetic fatty rats. Evid. Based Complement. Alternat. Med. 2011, 761859
18. Satoh, M., Fujimoto, S., Haruna, Y., Arakawa, S., Horike, H., Komai, N., Sasaki, T., Tsujioka, K., Makino, H. and Kashihara, N. (2005) NAD(P)H oxidase and uncoupled nitric oxide synthase are major sources of glomerular superoxide in rats with experimental diabetic nephropathy. Am. J. Physiol. Renal Physiol. 288, F1144-F1152
19. Asaba, K., Tojo, A., Onozato, M. L., Goto, A., Quinn, M. T., Fujita, T. and Wilcox, C. S. (2005) Effects of NADPH oxidase inhibitor in diabetic nephropathy. Kidney Int. 67, 1890-1898
20. Chawla T. Sharma, D. and Singh, A. (2010) Role of the renin angiotensin system in diabetic nephropathy. World J. Diabetes 1, 141-145
21. Thomas, M. C., Tikellis, C., Burns, W. M., Bialkowski, K., Cao, Z., Coughlan, M. T., Jandeleit-Dahm, K., Cooper, M. E. and Forbes, J. M. (2005) Interactions between renin angiotensin system and advanced glycation in the kidney. J. Am. Soc. Nephrol. 16, 2976-2984
22. Luis-Rodriguez D. Martinez-Castelao, A., Gorriz, J. L., De-Alvaro, F. and Navarro-Gonzalez, J. F. (2012) Pathophysiological role and therapeutic implications of inflammation in diabetic nephropathy. World J. Diabetes 3, 7-18
23. Saraheimo, M., Teppo, A. M., Forsblom, C., Fagerudd, J. and Groop, P. H. (2003) Diabetic nephropathy is associated with low-grade inflammation in Type 1 diabetic patients. Diabetologia 46, 1402-1407
24. Ziyadeh, F. N., Hoffman, B. B., Han, D. C., Iglesias-De La Cruz, M. C., Hong, S. W., Isono, M., Chen, S., McGowan, T. A. and Sharma, K. (2000) Long-term prevention of renal insufficiency, excess matrix gene expression, and glomerular mesangial matrix expansion by treatment with monoclonal antitransforming growth factor-β antibody in db/db diabetic mice. Proc. Natl. Acad. Sci. U.S.A. 97, 8015-8020
25. Sanchez, A. P. and Sharma, K. (2009) Transcription factors in the pathogenesis of diabetic nephropathy. Expert Rev. Mol. Med. 11, e13
26. Mezzano, S., Aros, C., Droguett, A., Burgos, M. E., Ardiles, L., Flores, C., Schneider, H., Ruiz-Ortega, M. and Egido, J. (2004) NF-κB activation and overexpression of regulated genes in human diabetic nephropathy. Nephrol. Dial. Transplant. 19, 2505-2512
27. Nam, J. S., Cho, M. H., Lee, G. T., Park, J. S., Ahn, C. W., Cha, B. S., Lim, S. K., Kim, K. R., Ha, H. J. and Lee, H. C. (2008) The activation of NF-κB and AP-1 in peripheral blood mononuclear cells isolated from patients with diabetic nephropathy. Diabetes Res. Clin. Pract. 81, 25-32
28. Hofmann, M. A., Schiekofer, S., Isermann, B., Kanitz, M., Henkels, M., Joswig, M., Treusch, A., Morcos, M., Weiss, T., Borcea, V. et al. (1999) Peripheral blood mononuclear cells isolated from patients with diabetic nephropathy show increased activation of the oxidative-stress sensitive transcription factor NF-κB. Diabetologia 42, 222-232
29. Yang, B., Hodgkinson, A., Oates, P. J., Millward, B. A. and Demaine, A. G. (2008) High glucose induction of DNA-binding activity of the transcription factor NF-κB in patients with diabetic nephropathy. Biochim. Biophys. Acta 1782, 295-302
30. Goldberg, H. J., Whiteside, C. I., Hart, G. W. and Fantus, I. G. (2006) Posttranslational, reversible O-glycosylation is stimulated by high glucose and mediates plasminogen activator inhibitor-1 gene expression and Sp1 transcriptional activity in glomerular mesangial cells. Endocrinology 147, 222-231
31. Ha, H., Yu, M. R., Choi, Y. J., Kitamura, M. and Lee, H. B. (2002) Role of high glucose-induced nuclear factor-κB activation in monocyte chemoattractant protein-1 expression by mesangial cells. J. Am. Soc. Nephrol. 13, 894-902
32. Park, C. W., Kim, J. H., Lee, J. H., Kim, Y. S., Ahn, H. J., Shin, Y. S., Kim, S. Y., Choi, E. J., Chang, Y. S. and Bang, B. K. (2000) High glucose-induced intercellular adhesion molecule-1 (ICAM-1) expression through an osmotic effect in rat mesangial cells is PKC-NF-κ B-dependent. Diabetologia 43, 1544-1553
33. Kumar, A., Hawkins, K. S., Hannan, M. A. and Ganz, M. B. (2001) Activation of PKC-βI in glomerular mesangial cells is associated with specific NF-κB subunit translocation. Am. J. Physiol. Renal. Physiol. 281, F613-F619
34. Lee, F. T., Cao, Z., Long, D. M., Panagiotopoulos, S., Jerums, G., Cooper, M. E. and Forbes, J. M. (2004) Interactions between angiotensin II and NF-κB-dependent pathways in modulating macrophage infiltration in experimental diabetic nephropathy. J. Am. Soc. Nephrol. 15, 2139-2151
35. Liang, Y. J., Jian, J. H., Liu, Y. C., Juang, S. J., Shyu, K. G., Lai, L. P., Wang, B. W. and Leu, J. G. (2010) Advanced glycation end products-induced apoptosis attenuated by PPARd activation and epigallocatechin gallate through NF-κB pathway in human embryonic kidney cells and human mesangial cells. Diabetes Metab. Res. Rev. 26, 406-416
36. Pillarisetti, S. and Saxena, U. (2004) Role of oxidative stress and inflammation in the origin of Type 2 diabetes: a paradigm shift. Expert Opin. Ther. Targets 8, 401-408
37. Ohga, S., Shikata, K., Yozai, K., Okada, S., Ogawa, D., Usui, H., Wada, J., Shikata, Y. and Makino, H. (2007) Thiazolidinedione ameliorates renal injury in experimental diabetic rats through anti-inflammatory effects mediated by inhibition of NF-κB activation. Am. J. Physiol Renal Physiol. 292, F1141-F1150
38. Zhang, Z., Yuan, W., Sun, L., Szeto, F. L., Wong, K. E., Li, X., Kong, J. and Li, Y. C. (2007) 1,25-Dihydroxyvitamin D3 targeting of NF-κB suppresses high glucose-induced MCP-1 expression in mesangial cells. Kidney Int. 72, 193-201
39. Lee, W. C., Chen, H. C., Wang, C. Y., Lin, P. Y., Ou, T. T., Chen, C. C., Wen, M. C., Wang, J. and Lee, H. J. (2010) Cilostazol ameliorates nephropathy in type 1 diabetic rats involving improvement in oxidative stress and regulation of TGF-β and NF-κB. Biosci. Biotechnol. Biochem. 74, 1355-1361
40. Soetikno, V., Sari, F. R., Veeraveedu, P. T., Thandavarayan, R. A., Harima, M., Sukumaran, V., Lakshmanan, A. P., Suzuki, K., Kawachi, H. and Watanabe, K. (2011) Curcumin ameliorates macrophage infiltration by inhibiting NF-κB activation and proinflammatory cytokines in streptozotocin induced-diabetic nephropathy. Nutr. Metab. 8, 35
41. Hasegawa G. Nakano, K., Sawada, M., Uno, K., Shibayama, Y., Ienaga, K. and Kondo, M. (1991) Possible role of tumor necrosis factor and interleukin-1 in the development of diabetic nephropathy. Kidney Int. 40, 1007-1012
42. Tarlow, J. K., Blakemore, A. I., Lennard, A., Solari, R., Hughes, H. N., Steinkasserer, A. and Duff, G. W. (1993) Polymorphism in human IL-1 receptor antagonist gene intron 2 is caused by variable numbers of an 86-bp tandem repeat. Hum. Genet. 91, 403-404
43. Blakemore, A. I., Cox, A., Gonzalez, A. M., Maskil, J. K., Hughes, M. E., Wilson, R. M., Ward, J. D. and Duff, G. W. (1996) Interleukin-1 receptor antagonist allele (IL1RN*2) associated with nephropathy in diabetes mellitus. Hum. Genet. 97, 369-374
44. Suzuki, D., Miyazaki, M., Naka, R., Koji, T., Yagame, M., Jinde, K., Endoh, M., Nomoto, Y. and Sakai, H. (1995) In situ hybridization of interleukin 6 in diabetic nephropathy. Diabetes 44, 1233-1238
45. Shelbaya, S., Amer, H., Seddik, S., Allah, A. A., Sabry, I. M., Mohamed, T. and El Mosely, M. (2012) Study of the role of interleukin-6 and highly sensitive C-reactive protein in diabetic nephropathy in type 1 diabetic patients. Eur. Rev. Med. Pharmacol. Sci. 16, 176-182
46. Shikano, M., Sobajima, H., Yoshikawa, H., Toba, T., Kushimoto, H., Katsumata, H., Tomita, M. and Kawashima, S. (2000) Usefulness of a highly sensitive urinary and serum IL-6 assay in patients with diabetic nephropathy. Nephron 85, 81-85
47. Sekizuka, K., Tomino, Y., Sei, C., Kurusu, A., Tashiro, K., Yamaguchi, Y., Kodera, S., Hishiki, T., Shirato, I. and Koide, H. (1994) Detection of serum IL-6 in patients with diabetic nephropathy. Nephron 68, 284-285
48. Svensson, M. K. and Eriksson, J. W. (2011) Change in the amount of body fat and IL-6 levels is related to altered insulin sensitivity in type 1 diabetes patients with or without diabetic nephropathy. Horm. Metab. Res. 43, 209-215
49. Vaidya, V. S., Niewczas, M. A., Ficociello, L. H., Johnson, A. C., Collings, F. B., Warram, J. H., Krolewski, A. S. and Bonventre, J. V. (2011) Regression of microalbuminuria in type 1 diabetes is associated with lower levels of urinary tubular injury biomarkers, kidney injury molecule-1, and N-acetyl-β-Dglucosaminidase. Kidney Int. 79, 464-470
50. Kalantarinia, K., Awad, A. S. and Siragy, H. M. (2003) Urinary and renal interstitial concentrations of TNF-a increase prior to the rise in albuminuria in diabetic rats. Kidney Int. 64, 1208-1213
51. Moriwaki, Y., Inokuchi, T., Yamamoto, A., Ka, T., Tsutsumi, Z., Takahashi, S. and Yamamoto, T. (2007) Effect of TNF-a inhibition on urinary albumin excretion in experimental diabetic rats. Acta Diabetol. 44, 215-218
52. Ferńandez-Real, J. M., Vendrell, J., Garćia, I., Ricart, W. and Vall'es, M. (2012) Structural damage in diabetic nephropathy is associated with TNF-a system activity. Acta Diabetol. 49, 301-305
53. Navarro, J. F. and Mora-Fernandez, C. (2006) The role of TNF-a in diabetic nephropathy: pathogenic and therapeutic implications. Cytokine Growth Factor Rev. 17, 441-450
54. Makino, N., Maeda, T., Sugano, M., Satoh, S., Watanabe, R. and Abe, N. (2005) High serum TNF-a level in Type 2 diabetic patients with microangiopathy is associated with eNOS down-regulation and apoptosis in endothelial cells. J. Diabetes Complications 19, 347-355
55. Fujita, T., Ogihara, N., Kamura, Y., Satomura, A., Fuke, Y., Shimizu, C., Wada, Y. and Matsumoto, K. (2012) Interleukin-18 contributes more closely to the progression of diabetic nephropathy than other diabetic complications. Acta Diabetol. 49, 111-117
56. Mahmoud, R. A., el-Ezz, S. A. and Hegazy, A. S. (2004) Increased serum levels of interleukin-18 in patients with diabetic nephropathy. Ital. J. Biochem. 53, 73-81 57 Moriwaki, Y., Yamamoto, T., Shibutani, Y., Aoki, E., Tsutsumi, Z., Takahashi, S., Okamura, H., Koga, M., Fukuchi, M. and Hada, T. (2003) Elevated levels of interleukin-18 and tumor necrosis factor-a in serum of patients with type 2 diabetes mellitus: relationship with diabetic nephropathy. Metabolism 52, 605-608
57. Moriwaki, Y., Yamamoto, T., Shibutani, Y., Aoki, E., Tsutsumi, Z., Takahashi, S., Okamura, H., Koga, M., Fukuchi, M. and Hada, T. (2003) Elevated levels of interleukin-18 and tumor necrosis factor-a in serum of patients with type 2 diabetes mellitus: relationship with diabetic nephropathy. Metabolism 52, 605-608
58. Nakamura, A., Shikata, K., Hiramatsu, M., Nakatou, T., Kitamura, T., Wada, J., Itoshima, T. and Makino, H. (2005) Serum interleukin-18 levels are associated with nephropathy and atherosclerosis in Japanese patients with type 2 diabetes. Diabetes Care 28, 2890-2895
59. Skopinski, P., Rogala, E., Duda-Krol, B., Lipinska, A., Sommer, E., Chorostowska-Wynimko, J., Szaflik, J., Partyka, I. and Skopinska-Rozewska, E. (2005) Increased interleukin-18 content and angiogenic activity of sera from diabetic (Type 2) patients with background retinopathy. J. Diabetes Complications 19, 335-338
60. Szeto, C. C., Chow, K. M., Poon, P. Y., Kwan, B. C. and Li, P. K. (2009) Association of interleukin-18 promoter polymorphism and atherosclerotic diseases in Chinese patients with diabetic nephropathy. Nephrology 14, 606-612
61. Uzu, T., Yokoyama, H., Itoh, H., Koya, D., Nakagawa, A., Nishizawa, M., Maegawa, H., Yokomaku, Y., Araki, S., Abiko, A. and Haneda, M. (2011) Elevated serum levels of interleukin-18 in patients with overt diabetic nephropathy: effects of miglitol. Clin. Exp. Nephrol. 15, 58-63
62. Wu, C. C., Sytwu, H. K., Lu, K. C. and Lin, Y. F. (2011) Role of T cells in type 2 diabetic nephropathy. Exp. Diabetes Res. 2011, 514738
63. Odobasic, D., Kitching, A. R., Tipping, P. G. and Holdsworth, S. R. (2005) CD80 and CD86 costimulatory molecules regulate crescentic glomerulonephritis by different mechanisms. Kidney Int. 68, 584-594
64. Wu, C. C., Chen, J. S., Lu, K. C., Chen, C. C., Lin, S. H., Chu, P., Sytwu, H. K. and Lin, Y. F. (2010) Aberrant cytokines/ chemokines production correlate with proteinuria in patients with overt diabetic nephropathy. Clin. Chim. Acta 411, 700-704
65. van Exel, E., Gussekloo, J., de Craen, A. J., Frolich, M., Bootsma-Van Der Wiel, A. and Westendorp, R. G. (2002) Low production capacity of interleukin-10 associates with the metabolic syndrome and type 2 diabetes: the Leiden 85-Plus Study. Diabetes 51, 1088-1092
66. Mysliwska, J., Zorena, K., Semetkowska-Jurkiewicz, E., Rachon, D., Suchanek, H. and Mysliwski, A. (2005) High levels of circulating interleukin-10 in diabetic nephropathy patients. Eur. Cytokine Network 16, 117-122
67. Bradshaw, E. M., Raddassi, K., Elyaman, W., Orban, T., Gottlieb, P. A., Kent, S. C. and Hafler, D. A. (2009) Monocytes from patients with type 1 diabetes spontaneously secrete proinflammatory cytokines inducing Th17 cells. J. Immunol. 183, 4432-4439
68. Honkanen, J., Nieminen, J. K., Gao, R., Luopajarvi, K., Salo, H. M., Ilonen, J., Knip, M., Otonkoski, T. and Vaarala, O. (2010) IL-17 immunity in human type 1 diabetes. J. Immunol. 185, 1959-1967
69. Jagannathan-Bogdan, M., McDonnell, M. E., Shin, H., Rehman, Q., Hasturk, H., Apovian, C. M. and Nikolajczyk, B. S. (2011) Elevated proinflammatory cytokine production by a skewed T cell compartment requires monocytes and promotes inflammation in type 2 diabetes. J. Immunol. 186, 1162-1172
70. Berthier C.C., Zhang, H., Schin, M., Henger, A., Nelson, R. G., Yee, B., Boucherot, A., Neusser, M. A., Cohen, C. D., Carter-Su, C. et al. (2009) Enhanced expression of Janus kinase-signal transducer and activator of transcription pathway members in human diabetic nephropathy. Diabetes 58, 469-477
71. Marrero, M. B., Banes-Berceli, A. K., Stern, D. M. and Eaton, D. C. (2006) Role of the JAK/STAT signaling pathway in diabetic nephropathy. Am. J. Physiol. Renal Physiol. 290, F762-F768
72. Wang, X., Shaw, S., Amiri, F., Eaton, D. C. and Marrero, M. B. (2002) Inhibition of the Jak/STAT signaling pathway prevents the high glucose-induced increase in TGF-β and fibronectin synthesis in mesangial cells. Diabetes 51, 3505-3509
73. Shi, Y. H., Zhao, S., Wang, C., Li, Y. and Duan, H. J. (2007) Fluvastatin inhibits activation of JAK and STAT proteins in diabetic rat glomeruli and mesangial cells under high glucose conditions. Acta Pharmacol. Sin. 28, 1938-1946
74. Banes-Berceli, A. K., Shaw, S., Ma, G., Brands, M., Eaton, D. C., Stern, D. M., Fulton, D., Caldwell, R. W. and Marrero, M. B. (2006) Effect of simvastatin on high glucose- and angiotensin II-induced activation of the JAK/STAT pathway in mesangial cells. Am. J. Physiol. Renal Physiol. 291, F116-F121
75. Park, J., Ryu, D. R., Li, J. J., Jung, D. S., Kwak, S. J., Lee, S. H., Yoo, T. H., Han, S. H., Lee, J. E., Kim, D. K. et al. (2008) MCP-1/CCR2 system is involved in high glucose-induced fibronectin and type IV collagen expression in cultured mesangial cells. Am. J. Physiol. Renal Physiol. 295, F749-F757
76. Kanamori, H., Matsubara, T., Mima, A., Sumi, E., Nagai, K., Takahashi, T., Abe, H., Iehara, N., Fukatsu, A., Okamoto, H. et al. (2007) Inhibition of MCP-1/CCR2 pathway ameliorates the development of diabetic nephropathy. Biochem. Biophys. Res. Commun. 360, 772-777
77. Nam, B. Y., Paeng, J., Kim, S. H., Lee, S. H., Kim do, H., Kang, H. Y., Li, J. J., Kwak, S. J., Park, J. T., Yoo, T. H. et al. (2012) The MCP-1/CCR2 axis in podocytes is involved in apoptosis induced by diabetic conditions. Apoptosis 17, 1-13
78. Sayyed, S. G., Ryu, M., Kulkarni, O. P., Schmid, H., Lichtnekert, J., Gruner, S., Green, L., Mattei, P., Hartmann, G. and Anders, H. J. (2011) An orally active chemokine receptor CCR2 antagonist prevents glomerulosclerosis and renal failure in type 2 diabetes. Kidney Int. 80, 68-78
79. Kang Y.S., Lee, M. H., Song, H. K., Ko, G. J., Kwon, O. S., Lim, T. K., Kim, S. H., Han, S. Y., Han, K. H., Lee, J. E. et al. (2010) CCR2 antagonism improves insulin resistance, lipid metabolism, and diabetic nephropathy in type 2 diabetic mice. Kidney Int. 78, 883-894
80. Ninichuk, V., Khandoga, A. G., Segerer, S., Loetscher, P., Schlapbach, A., Revesz, L., Feifel, R., Khandoga, A., Krombach, F., Nelson, P. J. et al. (2007) The role of interstitial macrophages in nephropathy of type 2 diabetic db/db mice. Am. J. Pathol. 170, 1267-1276
81. 'PEG prevents glomerulosclerosis and improves glomerular filtration rate in db/db mice. Am. J. Pathol. 172, 628-637
82. Tam, F. W., Riser, B. L., Meeran, K., Rambow, J., Pusey, C. D. and Frankel, A. H. (2009) Urinary monocyte chemoattractant protein-1 (MCP-1) and connective tissue growth factor (CCN2) as prognostic markers for progression of diabetic nephropathy. Cytokine 47, 37-42
83. Tesch, G. H. (2008) MCP-1/CCL2: a new diagnostic marker and therapeutic target for progressive renal injury in diabetic nephropathy. Am. J. Physiol. Renal Physiol. 294, F697-F701
84. Tashiro, K., Koyanagi, I., Saitoh, A., Shimizu, A., Shike, T., Ishiguro, C., Koizumi, M., Funabiki, K., Horikoshi, S., Shirato, I. and Tomino, Y. (2002) Urinary levels of monocyte chemoattractant protein-1 (MCP-1) and interleukin-8 (IL-8), and renal injuries in patients with type 2 diabetic nephropathy. J. Clin. Lab. Anal. 16, 1-4
85. Saitoh, A., Sekizuka, K., Hayashi, T., Kaneko, S., Suzuki, Y. and Tomino, Y. (1998) Detection of urinary MCP-1 in patients with diabetic nephropathy. Nephron 80, 99
86. Amann, B., Tinzmann, R. and Angelkort, B. (2003) ACE inhibitors improve diabetic nephropathy through suppression of renal MCP-1. Diabetes Care 26, 2421-2425
87. Kato, S., Luyckx, V. A., Ots, M., Lee, K. W., Ziai, F., Troy, J. L., Brenner, B. M. and MacKenzie, H. S. (1999) Renin-angiotensin blockade lowers MCP-1 expression in diabetic rats. Kidney Int. 56, 1037-1048
88. Tone, A., Shikata, K., Nakagawa, K., Hashimoto, M. and Makino, H. (2011) Renoprotective effects of clarithromycin via reduction of urinary MCP-1 levels in type 2 diabetic patients. Clin. Exp. Nephrol. 15, 79-85
89. Sayyed, S. G., Hagele, H., Kulkarni, O. P., Endlich, K., Segerer, S., Eulberg, D., Klussmann, S. and Anders, H. J. (2009) Podocytes produce homeostatic chemokine stromal cell-derived factor-1/CXCL12, which contributes to glomerulosclerosis, podocyte loss and albuminuria in a mouse model of type 2 diabetes. Diabetologia 52, 2445-2454
90. Darisipudi, M. N., Kulkarni, O. P., Sayyed, S. G., Ryu, M., Migliorini, A., Sagrinati, C., Parente, E., Vater, A., Eulberg, D., Klussmann, S. et al. (2011) Dual blockade of the homeostatic chemokine CXCL12 and the proinflammatory chemokine CCL2 has additive protective effects on diabetic kidney disease. Am. J. Pathol. 179, 116-124
91. Kikuchi, Y., Ikee, R., Hemmi, N., Hyodo, N., Saigusa, T., Namikoshi, T., Yamada, M., Suzuki, S. and Miura, S. (2004) Fractalkine and its receptor, CX3CR1, upregulation in streptozotocin-induced diabetic kidneys. Nephron. Exp. Nephrol. 97, e17-e25
92. Kikuchi, Y., Imakiire, T., Hyodo, T., Kushiyama, T., Higashi, K., Hyodo, N., Suzuki, S. and Miura, S. (2005) Advanced glycation end-product induces fractalkine gene upregulation in normal rat glomeruli. Nephrol. Dial. Transplant. 20, 2690-2696
93. Matsui, H., Suzuki, M., Tsukuda, R., Iida, K., Miyasaka, M. and Ikeda, H. (1996) Expression of ICAM-1 on glomeruli is associated with progression of diabetic nephropathy in a genetically obese diabetic rat, Wistar fatty. Diabetes Res. Clin. Pract. 32, 1-9
94. Clausen, P., Jacobsen, P., Rossing, K., Jensen, J. S., Parving, H. H. and Feldt-Rasmussen, B. (2000) Plasma concentrations of VCAM-1 and ICAM-1 are elevated in patients with Type 1 diabetes mellitus with microalbuminuria and overt nephropathy. Diabetic Med. 17, 644-649
95. Ye, S. D., Zheng, M., Zhao, L. L., Qian, Y., Yao, X. M., Ren, A., Li, S. M. and Jing, C. Y. (2009) Intensive insulin therapy decreases urinary MCP-1 and ICAM-1 excretions in incipient diabetic nephropathy. Eur. J. Clin. Invest. 39, 980-985
96. Okada, S., Shikata, K., Matsuda, M., Ogawa, D., Usui, H., Kido, Y., Nagase, R., Wada, J., Shikata, Y. and Makino, H. (2003) Intercellular adhesion molecule-1-deficient mice are resistant against renal injury after induction of diabetes. Diabetes 52, 2586-2593
97. Chow, F. Y., Nikolic-Paterson, D. J., Ozols, E., Atkins, R. C. and Tesch, G. H. (2005) Intercellular adhesion molecule-1 deficiency is protective against nephropathy in type 2 diabetic db/db mice. J. Am. Soc. Nephrol. 16, 1711-1722
98. Seron, D., Cameron, J. S. and Haskard, D. O. (1991) Expression of VCAM-1 in the normal and diseased kidney. Nephrol. Dial. Transplant. 6, 917-922
99. Narumi, S., Onozato, M. L., Tojo, A., Sakamoto, S. and Tamatani, T. (2001) Tissue-specific induction of E-selectin in glomeruli is augmented following diabetes mellitus. Nephron 89, 161-171
100. Jude, E. B., Douglas, J. T., Anderson, S. G., Young, M. J. and Boulton, A. J. (2002) Circulating cellular adhesion molecules ICAM-1, VCAM-1, P- and E-selectin in the prediction of cardiovascular disease in diabetes mellitus. Eur. J. Intern. Med. 13, 185-189
101. Albertini, J. P., Valensi, P., Lormeau, B., Aurousseau, M. H., Ferriere, F., Attali, J. R. and Gattegno, L. (1998) Elevated concentrations of soluble E-selectin and vascular cell adhesion molecule-1 in NIDDM. Effect of intensive insulin treatment. Diabetes Care 21, 1008-1013
102. Nakamura, K., Yamagishi, S., Adachi, H., Matsui, T., Kurita-Nakamura, Y., Takeuchi, M., Inoue, H. and Imaizumi, T. (2008) Serum levels of soluble form of receptor for advanced glycation end products (sRAGE) are positively associated with circulating AGEs and soluble form of VCAM-1 in patients with type 2 diabetes. Microvasc. Res. 76, 52-56
103. Jialal, I. and Kaur, H. (2012) The role of Toll-like receptors in diabetes-induced inflammation: implications for vascular complications. Curr. Diab. Rep. 12, 172-179
104. Li, F., Yang, N., Zhang, L., Tan, H., Huang, B., Liang, Y., Chen, M. and Yu, X. (2010) Increased expression of toll-like receptor 2 in rat diabetic nephropathy. Am. J. Nephrol. 32, 179-186
105. Devaraj, S., Tobias, P., Kasinath, B. S., Ramsamooj, R., Afify, A. and Jialal, I. (2011) Knockout of Toll-like receptor-2 attenuates both the proinflammatory state of diabetes and incipient diabetic nephropathy. Arterioscler. Thromb. Vasc. Biol. 31, 1796-1804
106. Lin, M., Yiu, W. H., Wu, H. J., Chan, L. Y., Leung, J. C., Au, W. S., Chan, K. W., Lai, K. N. and Tang, S. C. (2012) Toll-like receptor 4 promotes tubular inflammation in diabetic nephropathy. J. Am. Soc. Nephrol. 23, 86-102
107. Yilmaz, M. I., Saglam, M., Qureshi, A. R., Carrero, J. J., Caglar, K., Eyileten, T., Sonmez, A., Cakir, E., Oguz, Y., Vural, A. et al. (2008) Endothelial dysfunction in type-2 diabetics with early diabetic nephropathy is associated with low circulating adiponectin. Nephrol. Dial. Transplant. 23, 1621-1627
108. Ran, J., Xiong, X., Liu, W., Guo, S., Li, Q., Zhang, R. and Lao, G. (2010) Increased plasma adiponectin closely associates with vascular endothelial dysfunction in type 2 diabetic patients with diabetic nephropathy. Diabetes Res. Clin. Pract. 88, 177-183
109. Guo, L. L., Pan, Y. and Jin, H. M. (2009) Adiponectin is positively associated with insulin resistance in subjects with type 2 diabetic nephropathy and effects of angiotensin II type 1 receptor blocker losartan. Nephrol. Dial. Transplant. 24, 1876-1883
110. Kato, K., Osawa, H., Ochi, M., Kusunoki, Y., Ebisui, O., Ohno, K., Ohashi, J., Shimizu, I., Fujii, Y., Tanimoto, M. and Makino, H. (2008) Serum total and high molecular weight adiponectin levels are correlated with the severity of diabetic retinopathy and nephropathy. Clin. Endocrinol. 68, 442-449
111. Saraheimo, M., Forsblom, C., Fagerudd, J., Teppo, A. M., Pettersson-Fernholm, K., Frystyk, J., Flyvbjerg, A. and Groop, P. H. (2005) Serum adiponectin is increased in type 1 diabetic patients with nephropathy. Diabetes Care 28, 1410-1414
112. Jorsal, A., Tarnow, L., Frystyk, J., Lajer, M., Flyvbjerg, A., Parving, H. H., Vionnet, N. and Rossing, P. (2008) Serum adiponectin predicts all-cause mortality and end stage renal disease in patients with type I diabetes and diabetic nephropathy. Kidney Int. 74, 649-654
113. Javor, E. D., Moran, S. A., Young, J. R., Cochran, E. K., DePaoli, A. M., Oral, E. A., Turman, M. A., Blackett, P. R., Savage, D. B., O'Rahilly, S. et al. (2004) Proteinuric nephropathy in acquired and congenital generalized lipodystrophy: baseline characteristics and course during recombinant leptin therapy. J. Clin. Endocrinol. Metab. 89, 3199-3207
114. Suganami, T., Mukoyama, M., Mori, K., Yokoi, H., Koshikawa, M., Sawai, K., Hidaka, S., Ebihara, K., Tanaka, T., Sugawara, A. et al. (2005) Prevention and reversal of renal injury by leptin in a new mouse model of diabetic nephropathy. FASEB J. 19, 127-129
115. Wolf, G. and Ziyadeh, F. N. (2006) Leptin and renal fibrosis. Contrib. Nephrol. 151, 175-183 116 Chung, F. M., Tsai, J. C., Chang, D. M., Shin, S. J. and Lee, Y. J. (2005) Peripheral total and differential leukocyte count in diabetic nephropathy: the relationship of plasma leptin to leukocytosis. Diabetes Care 28, 1710-1717
116. Chung, F. M., Tsai, J. C., Chang, D. M., Shin, S. J. and Lee, Y. J. (2005) Peripheral total and differential leukocyte count in diabetic nephropathy: the relationship of plasma leptin to leukocytosis. Diabetes Care 28, 1710-1717
117. Chan, W. B., Ma, R. C., Chan, N. N., Ng, M. C., Lee, Z. S., Lai, C. W., Tong, P. C., So, W. Y. and Chan, J. C. (2004) Increased leptin concentrations and lack of gender difference in Type 2 diabetic patients with nephropathy. Diabetes Res. Clin. Pract. 64, 93-98
118. Fruehwald-Schultes, B., Kern, W., Beyer, J., Forst, T., Pfutzner, A. and Peters, A. (1999) Elevated serum leptin concentrations in type 2 diabetic patients with microalbuminuria and macroalbuminuria. Metab. Clin. Exp. 48, 1290-1293
119. Rudberg, S. and Persson, B. (1998) Serum leptin levels in young females with insulin-dependent diabetes and the relationship to hyperandrogenicity and microalbuminuria. Horm. Res. 50, 297-302
120. Sari, R., Balci, M. K. and Apaydin, C. (2010) The relationship between plasma leptin levels and chronic complication in patients with type 2 diabetes mellitus. Metab. Syndr. Relat. Disord. 8, 499-503
121. Sarnak, M. J., Poindexter, A., Wang, S. R., Beck, G. J., Kusek, J. W., Marcovina, S. M., Greene, T. and Levey, A. S. (2002) Serum C-reactive protein and leptin as predictors of kidney disease progression in the Modification of Diet in Renal Disease Study. Kidney Int. 62, 2208-2215
122. Verrotti, A., Basciani, F., De Simone, M., Morgese, G. and Chiarelli, F. (2001) Serum leptin changes during weight loss in obese diabetic subjects with and without microalbuminuria. Diabetes Nutr. Metab. 14, 283-287
123. Wilson, C., Nelson, R., Nicolson, M. and Pratley, R. (1998) Plasma leptin concentrations: no difference between diabetic Pima Indians with and without nephropathy. Diabetologia 41, 861-862
124. Levi, M., Wang, X. and Choudhury, D. (2011) Nuclear hormone receptors as therapeutic targets. Contrib. Nephrol. 170, 209-216
125. Overbergh, L., Decallonne, B., Valckx, D., Verstuyf, A., Depovere, J., Laureys, J., Rutgeerts, O., Saint-Arnaud, R., Bouillon, R. and Mathieu, C. (2000) Identification and immune regulation of 25-hydroxyvitamin D-1-a-hydroxylase in murine macrophages. Clin. Exp. Immunol. 120, 139-146
126. Deb, D. K., Chen, Y., Zhang, Z., Zhang, Y., Szeto, F. L., Wong, K. E., Kong, J. and Li, Y. C. (2009) 1,25-Dihydroxyvitamin D3 suppresses high glucose-induced angiotensinogen expression in kidney cells by blocking the NF-κB pathway. Am. J. Physiol. Renal Physiol. 296, F1212-F1218
127. Zhang, Z., Sun, L., Wang, Y., Ning, G., Minto, A. W., Kong, J., Quigg, R. J. and Li, Y. C. (2008) Renoprotective role of the vitamin D receptor in diabetic nephropathy. Kidney Int. 73, 163-171
128. Ohara, I., Tanimoto, M., Gohda, T., Yamazaki, T., Hagiwara, S., Murakoshi, M., Aoki, T., Toyoda, H., Ishikawa, Y., Funabiki, K. et al. (2011) Effect of combination therapy with angiotensin receptor blocker and 1,25-dihydroxyvitamin D3 in type 2 diabetic nephropathy in KK-Ay/Ta mice. Nephron Exp. Nephrol. 117, e124-e132
129. Deb, D. K., Sun, T., Wong, K. E., Zhang, Z., Ning, G., Zhang, Y., Kong, J., Shi, H., Chang, A. and Li, Y. C. (2010) Combined vitamin D analog and AT1 receptor antagonist synergistically block the development of kidney disease in a model of type 2 diabetes. Kidney Int. 77, 1000-1009
130. Zhang, Z., Zhang, Y., Ning, G., Deb, D. K., Kong, J. and Li, Y. C. (2008) Combination therapy with AT1 blocker and vitamin D analog markedly ameliorates diabetic nephropathy: blockade of compensatory renin increase. Proc. Natl. Acad. Sci. U.S.A. 105, 15896-15901
131. Sanchez-Nino, M. D., Bozic, M., Cordoba-Lanus, E., Valcheva, P., Gracia, O., Ibarz, M., Fernandez, E., Navarro-Gonzalez, J. F., Ortiz, A. and Valdivielso, J. M. (2012) Beyond proteinuria: VDR activation reduces renal inflammation in experimental diabetic nephropathy. Am. J. Physiol. Renal Physiol. 302, F647-F657
132. Plumand L. A. and Zella, J. B. (2012) Vitamin D compounds and diabetic nephropathy. Arch. Biochem. Biophys. 523, 87-94 133 Jiang, T., Wang, X. X., Scherzer, P., Wilson, P., Tallman, J., Takahashi, H., Li, J., Iwahashi, M., Sutherland, E., Arend, L. and Levi, M. (2007) Farnesoid X receptor modulates renal lipid metabolism, fibrosis, and diabetic nephropathy. Diabetes 56, 2485-2493
133. Jiang, T., Wang, X. X., Scherzer, P., Wilson, P., Tallman, J., Takahashi, H., Li, J., Iwahashi, M., Sutherland, E., Arend, L. and Levi, M. (2007) Farnesoid X receptor modulates renal lipid metabolism, fibrosis, and diabetic nephropathy. Diabetes 56, 2485-2493
134. Wang, X. X., Jiang, T., Shen, Y., Caldas, Y., Miyazaki-Anzai, S., Santamaria, H., Urbanek, C., Solis, N., Scherzer, P., Lewis, L. et al. (2010) Diabetic nephropathy is accelerated by farnesoid X receptor deficiency and inhibited by farnesoid X receptor activation in a type 1 diabetes model. Diabetes 59, 2916-2927
135. Park, C. W., Kim, H. W., Ko, S. H., Chung, H. W., Lim, S. W., Yang, C. W., Chang, Y. S., Sugawara, A., Guan, Y. and Breyer, M. D. (2006) Accelerated diabetic nephropathy in mice lacking the peroxisome proliferator-activated receptor a. Diabetes 55, 885-893
136. Park C.W., Zhang, Y., Zhang, X., Wu, J., Chen, L., Cha, D. R., Su, D., Hwang, M. T., Fan, X., Davis, L. et al. (2006) PPARa agonist fenofibrate improves diabetic nephropathy in db/db mice. Kidney Int. 69, 1511-1517
137. Tomizawa, A., Hattori, Y., Inoue, T., Hattori, S. and Kasai, K. (2011) Fenofibrate suppresses microvascular inflammation and apoptosis through adenosine monophosphate-activated protein kinase activation. Metab. Clin. Exp. 60, 513-522
138. Li, L., Emmett, N., Mann, D. and Zhao, X. (2010) Fenofibrate attenuates tubulointerstitial fibrosis and inflammation through suppression of nuclear factor-κB and transforming growth factor-β1/Smad3 in diabetic nephropathy. Exp. Biol. Med. 235, 383-391
139. Chen, L., Zhang, J., Zhang, Y., Wang, Y. and Wang, B. (2008) Improvement of inflammatory responses associated with NF-κB pathway in kidneys from diabetic rats. Inflamm. Res. 57, 199-204
140. Keech, A., Simes, R. J., Barter, P., Best, J., Scott, R., Taskinen, M. R., Forder, P., Pillai, A., Davis, T., Glasziou, P. et al. (2005) Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 366, 1849-1861
141. Balakumar, P., Kadian, S. and Mahadevan, N. (2012) Are PPARa agonists a rational therapeutic strategy for preventing abnormalities of the diabetic kidney? Pharmacol. Res. 65, 430-436
142. Asano, T., Wakisaka, M., Yoshinari, M., Iino, K., Sonoki, K., Iwase, M. and Fujishima, M. (2000) Peroxisome proliferator-activated receptor γ 1 (PPARγ 1) expresses in rat mesangial cells and PPARγ agonists modulate its differentiation. Biochim. Biophys. Acta 1497, 148-154
143. Nicholas, S. B., Kawano, Y., Wakino, S., Collins, A. R. and Hsueh, W. A. (2001) Expression and function of peroxisome proliferator-activated receptor-γ in mesangial cells. Hypertension 37, 722-727
144. Yang, T., Michele, D. E., Park, J., Smart, A. M., Lin, Z., Brosius, III, F. C., Schnermann, J. B. and Briggs, J. P. (1999) Expression of peroxisomal proliferator-activated receptors and retinoid X receptors in the kidney. Am. J. Physiol. 277, F966-F973
145. Bao, Y., Jia, R. H., Yuan, J. and Li, J. (2007) Rosiglitazone ameliorates diabetic nephropathy by inhibiting reactive oxygen species and its downstream-signaling pathways. Pharmacology 80, 57-64
146. Zheng, M., Ye, S., Zhai, Z., Chen, Y., Li, X., Yang, G., Fan, A. and Wang, Y. (2009) Rosiglitazone protects diabetic rats against kidney disease through the suppression of renal moncyte chemoattractant protein-1 expression. J. Diabetes Complications 23, 124-129
147. Qian, Y., Li, S., Ye, S., Chen, Y., Zhai, Z., Chen, K. and Yang, G. (2008) Renoprotective effect of rosiglitazone through the suppression of renal intercellular adhesion molecule-1 expression in streptozotocin-induced diabetic rats. J. Endocrinol. Invest. 31, 1069-1074
148. Kawai, T., Masaki, T., Doi, S., Arakawa, T., Yokoyama, Y., Doi, T., Kohno, N. and Yorioka, N. (2009) PPAR-γ agonist attenuates renal interstitial fibrosis and inflammation through reduction of TGF-β. Lab. Invest. 89, 47-58
149. Wang, W., Liu, F. and Chen, N. (2007) Peroxisome proliferator-activated receptor-γ (PPAR-γ) agonists attenuate the profibrotic response induced by TGF-β1 in renal interstitial fibroblasts. Mediators Inflamm. 2007, 62641
150. Ko, G. J., Kang, Y. S., Han, S. Y., Lee, M. H., Song, H. K., Han, K. H., Kim, H. K., Han, J. Y. and Cha, D. R. (2008) Pioglitazone attenuates diabetic nephropathy through an anti-inflammatory mechanism in type 2 diabetic rats. Nephrol. Dial. Transplant. 23, 2750-2760
151. Okada, T., Wada, J., Hida, K., Eguchi, J., Hashimoto, I., Baba, M., Yasuhara, A., Shikata, K. and Makino, H. (2006) Thiazolidinediones ameliorate diabetic nephropathy via cell cycle-dependent mechanisms. Diabetes 55, 1666-1677
152. Ye, S., Zheng, M., Hu, Y., Wu, F., Zhao, L. and Chen, Y. (2010) Hydrochloride pioglitazone decreases urinary monocyte chemoattractant protein-1 excretion in type 2 diabetics. Diabetes Res. Clin. Pract. 88, 247-251
153. Vijay, S. K., Mishra, M., Kumar, H. and Tripathi, K. (2009) Effect of pioglitazone and rosiglitazone on mediators of endothelial dysfunction, markers of angiogenesis and inflammatory cytokines in type-2 diabetes. Acta Diabetol. 46, 27-33
154. Cavender, M. A. and Lincoff, A. M. (2010) Therapeutic potential of aleglitazar, a new dual PPAR-α/γ agonist: implications for cardiovascular disease in patients with diabetes mellitus. Am. J. Cardiovasc. Drugs 10, 209-216
155. Arora, M. K., Reddy, K. and Balakumar, P. (2010) The low dose combination of fenofibrate and rosiglitazone halts the progression of diabetes-induced experimental nephropathy. Eur. J. Pharmacol. 636, 137-144
156. Matsushita, Y., Ogawa, D., Wada, J., Yamamoto, N., Shikata, K., Sato, C., Tachibana, H., Toyota, N. and Makino, H. (2011) Activation of peroxisome proliferator-activated receptor d inhibits streptozotocin-induced diabetic nephropathy through anti-inflammatory mechanisms in mice. Diabetes 60, 960-968